Method of cancer treatment

ABSTRACT

A method and composition for treating cancer comprising administering to a patient an effective amount of attenuated  Salmonella typhimurium  containing a plasmid carrying the coding sequence encoding a truncated human interleukin-2 and optionally an oil containing a high antioxidant concentration.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a continuation in part of and claims priorityof U.S. patent application Ser. No. 10/834,587, filed Apr. 29, 2004, thecontent of which is hereby incorporated by reference in its entirety.

REFERENCE TO SEQUENCE LISTING

A sequence listing on a compact disc is submitted with the presentapplication. The material on the compact disc is hereby incorporated byreference in its entirety.

BACKGROUND OF THE INVENTION

It is estimated that 150,000 new cases of colorectal cancer occur inNorth America every year. Of these patients, it is expected that 40 to50 percent will experience a recurrence within five years. Furthermore,it is known that the 75 to 80 percent of patients with a recurrence havethe liver as one of the involved sites for metastasis. Unresectablemetastatic carcinoma of the liver continues to have a very poorprognosis despite recent advances with chemotherapeutic andradiotherapeutic strategies, radiofrequency ablation and cryotherapy. Itis true that when caught at an early stage, Duke's stages A or B (i.e.,malignant invasion confined to the intestinal wall), a multimodalapproach of both surgery and chemotherapy have proven to be beneficial.However, when colorectal cancer metastasizes, it usually does so in theliver and if the metastases are unresectable there is currently noeffective treatment strategy with a reasonable hope of a cure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the pIL2 plasmid containing the coding sequence encodingthe human interleukin-2 protein inserted into Salmonella typhimuriumχ4550pIL2.

FIG. 2 shows the DNA sequence (SEQ ID NO:4) of a DNA encoding normalhuman interleukin-2.

FIG. 3 shows the amino acid sequence (SEQ ID NO:3) of the normal humaninterleukin-2 protein encoded by SEQ ID NO:4.

FIG. 4 is a bar graph representing (Tumor Treatment Model) reducedhepatic metastases in response to control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 5 shows a bar graph representing (Tumor Treatment Model) reducedhepatic tumor number in response to control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 6 shows a bar graph representing (Tumor Treatment Model) reducedhepatic tumor volume in response to control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 7 shows a bar graph representing (Tumor Treatment Model) elevatedhepatic NK cells in response to control (saline), Salmonella typhimuriumχ4550 and Salmonella typhimurium χ4550pIL2 with the truncated human IL-2gene.

FIG. 8 shows a bar graph representing (Tumor Treatment Model) elevatedhepatic CD8+ cells in response to control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 9 shows a bar graph representing (Tumor Treatment Model) reducedtumor number in response to saline, antioxidant oil, Salmonellatyphimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene plus antioxidant oil.

FIG. 10 shows a bar graph representing. (Tumor Treatment Model) reducedtumor volume in response to control (saline), antioxidant oil,Salmonella typhimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2with the truncated human IL-2 gene plus antioxidant oil.

FIG. 11 shows a graph representing (Tumor Prevention Model) improvedlong term survival in response to control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 12 shows a bar graph representing (Tumor Prevention Model)increased NK cell population in response to control (saline),antioxidant oil, Salmonella typhimurium χ4550pIL2 and Salmonellatyphimurium χ4550pIL2 with the truncated human IL-2 gene plusantioxidant oil.

FIG. 13 shows a bar graph representing (Tumor Prevention Model) CD8+cell, population in response to control (saline), antioxidant oil,Salmonella typhimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2with the truncated human IL-2 gene plus antioxidant oil.

FIG. 14 shows a bar graph representing (Tumor Prevention Model) CD4+ Thelper cell population in response to control (saline), oil, Salmonellatyphimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene plus antioxidant oil.

FIG. 15 shows a bar graph representing (Tumor Prevention Model) tumornumber in response to control (saline), antioxidant oil, Salmonellatyphimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene plus antioxidant oil.

FIG. 16 shows a bar graph representing (Tumor Prevention Model) tumorvolume in response to control (saline), antioxidant oil, Salmonellatyphimurium χ4550pIL2 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene plus antioxidant oil.

FIG. 17 shows is a bar graph showing the reduction in tumor size ofretroperitoneal neuromblastoma in control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 18 is a bar graph showing the reduction in tumor volume ofretroperitoneal neuromblastoma in control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 19 is a bar graph showing the reduction in tumor weight ofretroperitoneal neuromblastoma in control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 20 is a bar graph showing the reduction in tumor number ofpulmonary metastases from osteosarcoma in control (saline), Salmonellatyphimurium χ4550 and Salmonella typhimurium χ4550pIL2 with thetruncated human IL-2 gene.

FIG. 21 is a bar graph showing the reduction in number of hepaticmetastases in mice orally administered Salmonella-IL2 vs. saline(control) or SaS Salmonella-no-IL2.

FIG. 22 is a bar graph showing the reduction of liver metastases in micetreated with Salmonella-IL2 where NK and CD8+ cell populations weredepleted.

FIG. 23 is a bar graph showing that the invasion efficiency ofSalmonella-IL2 is greatest in hepatocytes, but Salmonella-IL2 alsoinvades various tumor cell lines.

FIG. 24 is a bar graph showing that the division efficiency ofSalmonella-IL2 is greatest within neuroblastoma and osteosarcoma tumorcell lines over a 24-hour period compared with hepatoma and colon cancercell lines.

FIG. 25 is a bar graph showing that the tumor volume (Panel A) andweight (Panel B) of retroperitoneal neuroblastoma in animals are reducedin mice treated with Salmonella-no-IL2 and Salmonella-IL2.

FIG. 26 is a bar graph showing serum cytokines at day 14 after gavagetreatment in retroperitoneal neuroblastoma.

SUMMARY OF THE INVENTION

The present invention provides a method for treating cancer. The methodincludes administering to a patient a composition comprising aneffective amount of attenuated Salmonella typhimurium containing aplasmid carrying a coding sequence encoding for a truncated humaninterleukin-2. An oil containing a high antioxidant concentrationselected from the group consisting of black raspberry oil, red raspberryoil, blackberry oil, marionberry oil, boysenberry oil, evergreenblackberry oil and black cumin oil is also optionally administered aspart of the method.

The present invention further provides the plasmid carrying the codingsequence encoding for truncated human interleukin-2 is pYA292.

The present invention also provides the attenuated Salmonellatyphimurium containing the coding sequence encoding for the truncatedhuman interleukin-2 lacks the cyclic AMP and cAMP receptor protein.

The present invention further provides the attenuated Salmonellatyphimurium lacking the enzyme aspartate semialdehyde dehydrogenase andthe pYA292 plasmid containing the enzyme aspartate semialdehydedehydrogenase, which renders the attenuated Salmonella typhimuriumharmless and simultaneously expresses the gene for human IL-2.

The present invention also provides the oil containing a highantioxidant concentration being extracted by using a high pressure pressand maintaining the temperature of the oil below one hundred twentydegrees Fahrenheit.

The present invention further provides a method wherein the codingsequence encoding truncated human interleukin-2 has an eighty percentidentity to SEQ ID NO:. 1

The present invention also provides a method wherein the coding sequenceencoding truncated human interleukin-2 has an eighty five percentidentity to SEQ ID NO:. 1

The present invention further provides a method wherein the codingsequence encoding truncated human interleukin-2 has a ninety percentidentity to SEQ ID NO: 1.

The present invention further provides a method wherein the codingsequence encoding truncated human interleukin-2 has a ninety fivepercent identity to SEQ ID NO: 1.

The present invention further provides a method wherein a dosecontaining approximately 10⁶ to 10⁸ of the attenuated Salmonellatyphimurium containing a plasmid carrying the coding sequence encodingthe truncated human interleukin-2 is administered once during treatmentand a dose of approximately a half teaspoon of an oil containing a highantioxidant concentration selected from the group consisting of blackraspberry oil, red raspberry oil, blackberry oil, marionberry oil,boysenberry oil, evergreen blackberry oil and black cumin oil isoptionally administered twice a day.

The present invention further provides a method of reducing murinehepatic metastases by oral treatment with attenuated Salmonellatyphimurium containing a plasmid carrying the coding sequence encodingthe truncated human interleukin-2.

The present invention further provides a method of reducing the volumeand mass of retroperitoneal neuroblastoma tumors in mice by oraltreatment with attenuated Salmonella typhimurium containing a plasmidcarrying the coding sequence encoding the truncated human interleukin-2.

The present invention further provides a method of reducing the numberand volume of pulmonary metastases in mice injected with osteosarcomacells and then given an oral treatment with attenuated Salmonellatyphimurium containing a plasmid carrying the coding sequence encodingthe truncated human interleukin-2.

DETAILED DESCRIPTION Definitions

“Attenuated” means bacteria selected or altered to greatly diminish itscapacity to cause disease, but still able to retain its ability tocolonize the gut associated lymphoid tissue.

“CD4+” and “CD4+ cell” mean a helper subset of T cells.

“CD8+” and “CD8+ cell” mean a cytotoxic subset of T cells.

“Coding sequence” and “coding region” are used interchangeably and referto a polynucleotide that encodes a protein and, when placed under thecontrol of appropriate regulatory sequences, expresses the encodedprotein. The boundaries of a coding region are generally determined by atranslation start codon at its 5′ end and a translation stop codon atits 3′ end.

“Gated Lymphocytes” refers to lymphocytes that have been analyzed in afluorescent cell sorter.

“IL-2” means the protein human interleukin-2.

“NK” or “NK cell” means natural killer cell.

“Oil” refers to highly potent antioxidant oils.

“Operably linked” refers to a juxtaposition wherein the components sodescribed are in a relationship permitting them to function in theirintended manner. A regulator sequence is operably linked to a codingregion when it is joined in such a way that expression of the codingregion is achieved under conditions compatible with the regulatorysequence.

“Regulatory Sequence” refers to a nucleotide sequence that regulatesexpression of a coding region to which it is operably linked.Nonlimiting examples of regulatory sequences include promoters,transcription initiation sites, translation start sites, translationstop sites and terminators.

Human Interleukin-2

Interleukin-2 (IL-2) (SEQ ID NO: 3, FIG. 3) is a protein naturallyproduced by the human body which promotes lymphocyte proliferation andenhances the cytolytic function of T cells and natural killer (NK)cells. It is thus able to stimulate the immune system to producecancer-destroying white blood cells. IL-2 based immunotherapy in certaintypes of cancer has been studied for years with limited success.

Attenuated Salmonella typhimurium

While IL-2 is naturally produced by the human body, its maximumeffectiveness requires a higher concentration and more specific deliveryvector to the disease site. However, high doses of IL-2 are found toresult in severe toxicity in many patients. A solution to this problemwas found in using a live bacterial strain of Salmonella typhimuriumwhich was attenuated to greatly diminish its capacity to cause disease.S. typhimurium is used due to its natural ability to colonize the gutassociated lymphoid tissue (GALT), liver and spleen. Colonization of theliver by the attenuated S. typhimurium further initiates a generalizedcellular response against the bacteria or can persist as a carrierstate. The χ4550 strain of S. typhimurium used in the present inventioncontains a gene deletion constructed by transposon mutagenesis with Tn10followed by selection for furasic acid resistance. This method ofgenetic alteration leads to deletional loss of Tn10 and adjacent DNAsequences to produce a deletion of aspartate semialdehyde dehydrogenase(asd). This mutation imposes a requirement for diaminopimelic acid. Thelack of the asd enzyme in these bacteria leads to the inability toconstruct a stable cell wall causing lethal lysis of the S. typhimurium.Thus, to insure stable expression of a desired protein, aplasmid-(pYA292) was constructed which carries the asd gene. In order toinsure avirulence of the S. typhimurium strain, standard P22 phagetransduction of the mouse virulent S. typhimurium SR-11 strain χ3306 wasemployed to construct the χ4550 strain that lacks the ability tosynthesize adenylate cyclase and the cAMP receptor protein (CRP). CyclicAMP and cAMP receptor protein are necessary for the transcription ofmany genes and operons concerned with the transport and breakdown ofcatabolites. Although cAMP is found in mammalian tissue andtheoretically could be used by the bacteria to increase the potentialfor virulence, the lack of a cAMP receptor protein should abolish anybenefit that could occur by the uptake of cAMP by these mutant bacteria.

A synthetic cDNA (SEQ ID NO: 5), coding for a truncated human IL-2protein, optimized for expression in Escherichia coli was inserted intoplasmid pYA292 using well known methods. The truncated cDNA (SEQ IDNO:1) is a part of the synthetic IL-2 nucleotide sequence (SEQ ID NO:5). This sequence is one nucleotide short of the sequence that wasintended to code for a full-length mature human IL-2 protein. By“mature” is meant a protein lacking the beginning (N-terminal) 20 aminoacid signal sequence that is cleaved off as the molecule is secretedfrom the a human cell. The mutation that occurred is a deletion of a “t”nucleotide between the “a” at position 272 and the “g” at position 273.This resulted in an in-frame taa stop codon at position 274 thattruncated the resultant IL-2 protein. The resulting DNA nucleotidesequence is SEQ ID NO: 1 and the expressed protein is SEQ ID NO: 2. Boththe aspartate semialdehyde dehydrogenase (asd+) vector and the synthetictruncated human IL-2 cDNA were digested to completion with restrictionenzymes EcoRI (Promega, Madison, Wis.) and Hind III (New EnglandBiolabs, Beverly, Mass.). The ˜3.4 kb linearized vector fragment ofpYA292 and the EcoRI-HindIII fragment of the IL-2 gene were isolatedfollowing agarose gel electrophoresis using the PrepaGene Kit (BioRad,Hercules, Calif.). The IL-2 gene fragment was ligated into the pYA292vector using T4 DNA ligase (Promega, Madison, Wis.) with a 3:1 molarexcess of insert and incubating for 4 hours at 16° C. The ligation mixwas then electroporated into the χ4550 strain of attenuated S.typhimurium. S. typhimurium, Δcya-1 Δcrp-1 ΔasdA1 strain χ4550, wasgrown in Luria Broth (Sigma, St. Louis, Mo.) containing 50 mg/mldiaminopimelic acid (DAP). Cultures were grown to an absorbance of 0.200at OD₆₀₀ (approximately 10⁸ colony forming units (CFU)/ml broth) and thecells were prepared for electroporation. Plasmid vector pYA292 and theligation mix were electroporated into χ4550 utilizing an electroporationdevice (BioRad) with 0.2 cm disposable cuvettes. Cells were pulsed at2.5 kV and 25 μF with a pulse controller at 200 ohms. Cells were thensubsequently plated on Luria agar without DAP and recombinant cloneswere identified using the Magic Mini-Prep DNA Purification System(Promega), and restriction enzyme digestion with EcoRI and HindIII andgel electrophoresis with 1.2 agarose. The restriction enzyme mappingrevealed a plasmid corresponding to that expected for an insert of theIL-2 fragment in pYA292 and the plasmid was renamed pIL2. The newtransformant was renamed χ4550(pIL2). Transforming an asd deleted strainwith the plasmid (pIL2) allows for the stable expression of IL-2.

As discussed above, stability of this vector is maintained because theparticular strain of S. typhimurium used here (χ4550) lacks the enzymeaspartate semialdehyde dehydrogenase (asd), which, conversely, theplasmid containing the IL-2 gene (pIL2) contains. Bacteria lacking asdcannot make diaminopimelic acid (DAP), an essential component of thebacterial cell wall and, thus, would not long survive. Thus, if theattenuated S. typhimurium were to attempt to revert to its wild-typestrain and lose the plasmid, it would die a “DAP-less” death. Becausethe loss of the IL-2 containing plasmid would also result in the loss ofthe plasmid encoded asd, stable expression of the IL-2 gene is achieved.

It is believed that a coding sequence encoding truncated humaninterleukin-2 having an eighty percent identity to SEQ ID NO: 1 would beeffective in the treating and preventing cancerous tumors. It is furtherbelieved that a coding sequence encoding truncated human interleukin-2having an eighty five percent identity to SEQ ID NO: 1 would beeffective in treating and preventing cancerous tumors. It is alsobelieved that a coding sequence encoding truncated human interleukin-2having a ninety percent identity to SEQ ID NO: 1 would be effective intreating and preventing cancerous tumors. It is further believed that acoding sequence encoding truncated human interleukin-2 having a ninetyfive percent identity to SEQ ID NO: 1 would be effective in treating andpreventing cancerous tumors.

High Antioxidant Plant Oils

Natural oils derived from plant materials are produced through a methodof cold pressing the raw plant material. In a preferred embodiment wasteproducts of black raspberries, Rubus occidentalis L. pulp fiberincluding seeds is recovered and dried to a moisture content of lessthan 10 percent in a low temperature dryer having rapid air flow andwith temperatures not exceeding 120 degrees Fahrenheit. Rapid drying ofthe seed and pulp material is important to prevent the growth ofmicroorganisms and decay. Following drying, the seeds are separated fromthe pulp using a seed cleaner.

The seeds are then carefully pressed in a cold press where temperaturesof the extracted oil do not exceed 120 degrees Fahrenheit. A Komet™single or double screw expeller, Model DD85, manufactured by IBGMontforts GmbH was used. Other cold presses are commercially availableand could also satisfactorily be used to extract the oil. Typically thepress achieves pressures of 1200 pounds per square inch against the seedmaterial and press head. The press may be electrically driven or drivenby other mechanical means. The press cylinder, where the oil exits thepress, may be enclosed within a hood and put under pressure of an inertgas such as nitrogen or carbon dioxide to prevent the freshly expelledoil from contact with oxygen to enhance the oxidative stability of theoil. To start the process no external heat is used. This is unlike otherconventional pressing methods for grains and vegetable oils which addheat to the pressing head. Using a speed of 20 to 100 rpm of the Komet™press, the oil is extracted at ambient temperatures of 70 to 90 degreesFahrenheit. A nozzle at the press head having a round aperture rangingfrom 6 mm to 15 mm allows the solid seed material to be expelled fromthe press. The oil flows by gravity to a collection container. In oneembodiment the fresh, carefully expelled oil is allowed to settle to thebottom of the container and the oil clarifies. In another embodiment theoil is collected and used in an unsettled condition. A filter can alsobe used for separation of the fine fiber material from the oil. The oilis then decanted for further storage and bottling.

The resulting oil is extremely high in antioxidants, as the followingtables show:

TABLE 1 Sterols Cholesterol <1.0 mg/100 g Campesterol 26.2 mg/100 gStigmasterol 10.2 mg/100 g Beta Sitosterol  461 mg/100 g

TABLE 2 Fatty Acid Composition of Black Raspberry Seed Oil Fatty Acidgrams/1.00 g Myristic nd Palmitic 1.2-1.6 Palmitoleic nd Stearic  0.1Oleic 6.1-7.7 Linoleic 55.8-57.6 Arachidonic nd Total Sat 1.2-1.6 TotalMUFA 6.1-7.7 Total ω-3 FA 35.2 Total PUFA 91.1-93.0 nd = not detectable.MUFA and PUFA represent mono and polyunsaturated fatty acids. ω-3 FA =ω-3 fatty acids.

TABLE 3 Vitamin E Total Tocotrienol grams/100 g Alpha Tocotrienol <.500mg Beta Tocotrienol  2.42 mg Delta Tocotrienol <.500 mg GammaTocotrienol  3.10 mg

TABLE 4 Total Tocopherol grams/100 g Alpha Tocopherol  1.64 mg BetaTocopherol <.500 mg Gamma Tocopherol  6.05 mg Delta Tocopherol <.500 mg

TABLE 5 Antioxidant Property of Black Raspberry Seed Oil ABTS⁺Scavenging Activity (μmole TE/g) 0/3-0/7 DPPH Scavenging Activity (%DPPH 11.4-53.4 quenched TPC (μg GE/g) 35.1-92.6 ABTS⁺ scavengingactivity was evaluated using the radical cation generated by a chemicalmethod. DPPH scavenging activity was measured at a final concentrationof 42 mg oil equivalent/mL or 125 μg meal equivalent/mL in theradical-antioxidant reaction mixture. TPC = total phenolic content andis expressed as gallic acid equivalent (GE). The TPC was measured usingthe Folin-Ciocalteu reagent. Values were means of triplicatemeasurements.

Methods for Tests

Fatty Acid Analysis. One mg of each oil sample was used to prepare thefatty acid methyl esters (FAME) for gas chromatograph (GC) analysis. TheGC analysis of the FA composition was performed on a HP® 6890 gaschromatograph equipped with an autosampler, Chemstation and FID (HewlittPackard Co., Avondale, Pa.). A fused silica capillary column SP™-2380(30 m×0.25 mm with a 0.25 μm film thickness) from Supelco (Bellafonte,Pa.) was used with helium as the carrier gas. The following temperatureprogram was used: 165° C. for 20 min followed by a 5°/Cmin increase to185° C., which was then held for 10 min.

Radical Cation ABTS Scavenging Activity. Radical scavenging capacity ofblack raspberry antioxidant was evaluated against ABTS⁺ generated by thechemical method. 50 μL of black raspberry antioxidants in 50% acetonewas diluted with 450 μL of 7% RMCD to obtain the testing samples. ABTS⁺was prepared by oxidizing 5 mM aqueous solution of ABTS,2,2′-azinobis(3-ethylbenothiazoline-6-sulfonic acid diammonium salt,with manganese dioxide at ambient temperatures for 30 minutes. The ABTS⁺antioxidant reaction mixture contained 1.0 mL of ABTS⁺ with anabsorbance of 0.7 at 734 nm, and 80 μL of 7% RMCD solution for thecontrol. The absorbance at 734 nm was measured at 1 min of the reaction,and the trolox equivalent was calculated using a standard curve preparedwith trolox.

Radical DPPH Scavenging Activity. Free radical scavenging capacity ofblack raspberry oil was determined according to the previously describedprocedure using the stable 2,2′-diphenyl-1-picryhydrazyl radical (DPPH).The final concentration was 100 μM for DPPH. The absorbance at 517 nmwas measured against a blank of pure ethanol at 40 and used to estimatethe remaining radical levels according to a standard curve.

Total Phenolic Contents. The total phenolic content of black raspberryseed oil was determined using the Folin-Ciocalteu reagent. In brief, thereaction mixture contained 50 μL of the Folin-Ciocalteu reagent freshlyprepared in the laboratory and 0.75 mL of 20% sodium carbonate and 3 mLof pure water. After two hours of reaction at ambient temperature, theabsorbance at 765 nm was measured and used to calculate the phenoliccontents using gallic acid as a standard.

As indicated above, black raspberry oil has very high concentrations oftotal vitamin E, tocotrienol, and tocopherols, even higher that otherfruit oils from cranberry and grape. Tocotrienols are increasingly beingrecognized as having an important role in preventing degenerativediseases. Gamma tocopherol, the most potent antioxidant of all thetocopherols is higher in black raspberry oil than in cranberry oil andcontributes to oxidative stability of the unsaturated oils in blackraspberry oil. The presence of high concentrations of both tocotrienoland tocopherols is unusual as other vegetable oils are more typicallyhigh in either tocotrienol or tocopherol but not both.

In another embodiment the oil can be extracted from the raw plantmaterial using Super Critical Fluid Extraction technology. SuperCritical Fluid Extraction uses CO₂ under pressure to enter the cellwalls of the plant material to force the separation of oils andextracts. By varying temperature and pressure different separations orfractions can be achieved. Because the process works at low temperatureand in the absence of oxygen, the resulting oil is of high quality andunaltered from its natural form. While black raspberry oil appears to bethe most promising, it should be mentioned that other natural oils suchas those derived from black cumin seed, caneberries (raspberry,blackberry, marionberry, boysenberry and evergreen blackberry),coriander, sea buckthorn, palm fruit oil and cardomon are also known tobe high in antioxidants. Finally, combinations of the various oilsdiscussed above are also contemplated by the invention and are thereforewithin its scope.

I. Murine Hepatic Metastases from Adenocarcinoma Cells.

The following paragraph is for background information only and is notintended to constitute an admission of prior art.

Experimental data was reported in Saltzman, Heise, Hasz, Zebede, Kelly,Curtiss, Leonard, and Anderson, “Attenuated Salmonella typhimuriumContaining Interleukin-2 Decreases MC-38 Hepatic Metastases: a NovelAnti-Tumor Agent,” Cancer Biotherapy and Radiopharmaceuticals 11:2(1996). At the time, it was believed that the plamid pIL2 contained DNA(SEQ ID NO: 6) encoding normal interleukin-2 (SEQ ID NO: 3). However, itwas recently discovered that the DNA (SEQ ID NO: 5) in the plasmid pIL2contained a single basepair deletion encoding a truncated protein (SEQID NO: 2). This was recently noted in Sorenson, Banton, Frykman,Leonard, and Saltzman, “Attenuated Salmonella typhimurium with IL-2 GeneReduces Pulmonary Metastases in Murine Osteosarcoma,” Clin Orthop RelatRes (2008) 466: 1285-1291. Neither of the above-noted publicationsdiscloses the nucleotide sequence (SEQ ID NO:1) for the truncated DNA orthe amino acid sequence (SEQ ID NO:2) for the truncated protein.

The following discussion refers to the truncated DNA and protein.

Two basic tumor models were used to examine the efficacy of this novelanti-tumor system on hepatic metastases from adenocarcinoma cells: aTumor Treatment Model and a Tumor Prevention Model.

In the Tumor Treatment Model female 6 to 8 week old C57BL/6 mice werepurchased from Harlan Sprague-Dawley (Indianapolis, Ind.). At the onsetof each experiment, the mice were randomly divided into four groups(Control, Salmonella typhimurium-IL-2, antioxidant oil alone andSalmonella typhimurium IL-2 with antioxidant oil) that were orallyinoculated with saline or 10⁸ S. typhimurium χ4550pIL2 and received astandard rodent diet or a standard rodent diet supplemented withantioxidant oil for the duration of the experiment. The procedureyielded four groups: saline, antioxidant oil, S. typhimurium χ4550pIL2,and S. typhimurium χ4550pIL2+ antioxidant oil. Mice in the antioxidantoil and S. typhimurium χ4550pIL2+ antioxidant oil groups received astandard rodent diet supplemented with black raspberry seed oil fromBotanic Oil Innovation, Inc. (Spooner, Wis.) at a concentration of tenpercent by weight. In order to incorporate the antioxidant oil into thediet, it was necessary to crush the standard rodent diet pellets to theconsistency of coarse sand. To negate any possible variation in foodconsumption due to the form of the diet, all groups received a crusheddiet. Mice were fed their respective diets and water ad libitum.25,000-100,000 MCA murine adenocarcinoma cells were injected into thespleen to facilitate hepatic metastases via the portal circulation onDay 0. On Day 3 the mice were randomized into their groups and treated.On Day 12 of experimentation, mice were sacrificed and liver metastaseswere enumerated for number and volume of tumor.

In the Tumor Prevention Model, at the onset of each experiment, micewere administered the control (saline), antioxidant oil, S. typhimuriumχ4550pIL2 with and without the antioxidant oil on Day 0. On Day 7splenic injection of 50,000 MCA-38 adenocarcinoma cells wasaccomplished. On Day 14 hepatic metastases were enumerated for tumornumber and volume. Total tumor volume was calculated assuming tumorshape as a sphere (4/3 r³). Hepatic lymphocytes were also analyzed fromeach experimental.

Experiments were concluded at 3, 7 or 14 days following oral inoculationand all mice were sacrificed under anesthesia. A splenectomy wasperformed to allow for splenic lymphocyte analysis. Splenic lymphocyteswere prepared by modifying a technique used to isolate hepaticlymphocytes. Briefly, the spleen was mechanically minced, passed through100-gauge nylon mesh (Sefar America, Inc., Kansas City, Mo.), andsuspended in DMEM (Sigma, St. Louis, Mo.) with 10% fetal goat serum(Sigma). Individual specimens were place on lymphocyte separation medium(Mediatech, Inc., Herndon, Va.) and centrifuged at 300 g for 60 minutesat room temperature. The mononuclear cell layer was harvested and washedtwice in phosphate buffered solution (Gibco, Grand Island, N.Y.) withcentrifugation at 300 g for 10 minutes at room temperature.

Splenic lymphocytes were stained with a combination offluorochrome-conjugated anti-mouse monoclonal antibodies, includinganti-NK1.1, anti-CD4, and anti-CD8 (all obtained from BD BiosciencesPharmingen, San Diego, Calif.). Lymphocyte staining was performed at 4°C. for 30 minutes by incubating the cells with monoclonal antibodies.After washing, analysis was performed with a FACScan cytofluorometer(Becton-Dickinson, Grenoble, France) using CellQuest software(Becton-Dickinson). Viable lymphocytes were gated by side and forwardscatter profiles. For each specimen, analysis was based on 10,000acquired events.

Statistical analyses were performed using StatView 5.0 (SAS Institute,Cary, N.C.). At the conclusion of an experiment, splenic lymphocytephenotype was analyzed by analysis of variance followed by Fisher's testfor significant difference. Experiments were repeated twice on separatedays to verify reproducibility. Statistical significance was regarded asP<0.05.

Examples Tumor Treatment Model

FIG. 4 shows the results of the control, S. typhimurium χ4550 and S.typhimurium χ4550pIL2 groups on hepatic metastases when administeredorally to tumor burdened mice. A statistically significant decrease inhepatic colorectal metastases is shown. There was a mean of 106.4metastases in the control group, a mean of 103.7 metastases in the groupfed bacteria without the gene for truncated IL-2, and a mean of 44.3metastases in the group fed bacteria with the gene for truncated IL-2.

FIG. 5 shows additional results of the control, S. typhimurium χ4550 andS. typhimurium χ4550pIL2 groups on tumor number when administered orallyto tumor burdened mice. A statistically significant reduction in tumornumber is shown.

FIG. 6 shows the results of the control, S. typhimurium χ4550 and S.typhimurium χ4550pIL2 groups on tumor volume when administered orally totumor burdened mice. A statistically significant reduction in tumorvolume is shown.

FIG. 7 shows the results of the control, S. typhimurium χ4550 and S.typhimurium χ4550pIL2 groups on NK cells when administered orally totumor burdened mice. An increase in NK cells is shown in the S.typhimurium χ4550 and S. typhimurium χ4550pIL2 groups when compared tothe control group.

FIG. 8 shows the results of the control, S. typhimurium χ4550 and S.typhimurium χ4550pIL2 groups on CD8+ cells when administered orally totumor burdened mice. An increase in CD8+ cells is shown in the S.typhimurium χ4550 and S. typhimurium χ4550pIL2 groups when compared tothe control group.

FIG. 9 shows the results of the four groups (control, oil, S.typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidant oilon total tumor number in tumor burdened mice. As shown, the S.typhimurium χ4550pIL2 plus antioxidant oil group had approximately aneight fold reduction in total number of tumor cells compared to thegroup receiving only oil. An approximate two fold reduction in thenumber of tumors was shown compared to the group receiving only S.typhimurium χ4550pIL2. Compared to the control group, the groupreceiving S. typhimurium χ4550pIL2 plus antioxidant oil showed a fourfold reduction in the number of tumors.

FIG. 10 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2+ antioxidant oil)on tumor volume in tumor burdened mice. As shown the S. typhimuriumχ4550pIL2 plus antioxidant oil group showed almost negligible tumorvolume compared to the antioxidant oil only group, the control group,and the S. typhimurium χ4550pIL2 only group.

Examples Tumor Prevention Model

FIG. 11 shows the cumulative survival of tumor naive mice after beingfed control, S. typhimurium χ4550 and S. typhimurium χ4550pIL2, Thegroups receiving S. typhimurium χ4550 and S. typhimurium χ4550pIL2 showan almost 40% long term survival rate over the control group.

FIG. 12 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidantoil) on NK cell population in tumor naive mice. A statisticallysignificant increase over the control group and antioxidant oil onlygroup is shown in the S. typhimurium χ4550pIL2 and S. typhimuriumχ4550pIL2 plus antioxidant oil groups.

FIG. 13 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidantoil) on CD8+ cell population in tumor naive mice. A slight increase inCD8+ T cell population is shown in the mice in the S. typhimuriumχ4550pIL2 plus antioxidant oil group.

FIG. 14 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidantoil) on CD4+ T helper cell population in tumor naive mice. An overallstatistically significant increase in CD4+ T helper cell population isshown in the S. typhimurium χ4550pIL2 plus antioxidant oil group.

FIG. 15 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidantoil) on tumor number in tumor naive mice. A statistically significantdecrease in tumor number is shown in the S. typhimurium χ4550pIL2 and S.typhimurium χ4550pIL2 plus antioxidant oil groups.

FIG. 16 shows the results of the four groups (control, antioxidant oil,S. typhimurium χ4550pIL2 and S. typhimurium χ4550pIL2 plus antioxidantoil) on tumor volume in tumor naive mice. A statistically significantdecrease in tumor volume is observed in the S. typhimurium χ4550pIL2group, with a further decrease observed in the S. typhimurium χ4550pIL2antioxidant oil group.

Treatment of Retroperitoneal Neuroblastoma.

The following paragraph is for background information only and is notintended to constitute an admission of prior art.

Experimental data was reported in Daniel A. Saltzman, “CancerImmunotherapy based on the Killing of Salmonella typhimurium-infectedTumour Cells,” Expert Opin. Biol. Ther. (2005) 5(4): 443-449. At thetime, it was believed that the plamid pIL2 contained DNA (SEQ ID NO: 6)encoding normal interleukin-2 (SEQ ID NO: 7). However, it was recentlydiscovered that the DNA in the plasmid pIL2 was actually a singlebase-pair deleted DNA (SEQ ID NO:5) encoding a truncated protein (SEQ IDNO: 2). This was recently noted in Sorenson, Banton, Frykman, Leonard,and Saltzman, “Attenuated Salmonella typhimurium with IL-2 Gene ReducesPulmonary Metastases in Murine Osteosarcoma,” Clin Orthop Relat Res(2008) 466: 1285-1291. Neither of the above-noted publications disclosesthe nucleotide sequence (SEQ ID NO:1) for the truncated DNA or the aminoacid sequence (SEQ ID NO:2) for the truncated protein.

The following data are for the truncated DNA and protein.

Neuroblastoma is the most common malignancy in infants and the mostcommon extracranial solid tumor of childhood. Infants and children withconfined disease have a >80% chance of cure, whereas older children withmetastatic disease have only a 20-25% cure rate. Although neuroblastomaaccounts for only ˜10% of all childhood tumors, it is responsible for15% of all cancer-related deaths in the pediatric age group. Multipletherapies are being studied to treat these children with state IVdisease, including radioactive iodine-131-meta-iodobenzylguanidine(MIBG) therapy, antiobiotics directed at the ganglioside GD2, and13-cis-retinoic acid therapy combined with chemotherapy. These therapieshave shown inconsistent response rates towards treatment, and ongoingstudies continue to delve into their utility.

Due to the finding of an increase of Salmonella invasion and divisionefficiency in neuroblastoma cells, the antitumor effect of Salmonella ina preclinical murine model of a retroperitoneal neuroblastoma wasstudied. In these experiments, it was found that treatment with S.typhimurium or Salmonella-pIL2 in those mice with retroperitonealneuroblastomata resulted in a significant reduction in tumor volume(749.5 and 332.4 mm3, respectively) when compared with saline controls(2024.3 mm3; p<0.00001) (FIG. 18). Treatment with S. typhimurium orSalmonella-pIL2 is also associated with a reduction in tumor weight(0.88 and 0.377 grams, respectively) when compared with saline controls(2.218 grams; p<0.0001) (FIG. 19). When comparing reductions between S.typhimurium and Salmonella-pIL2 treated animals, there is a decrease intumor volume (749.5 and 332.4 mm3; p<0.0001) and in tumor weight (0.88and 0.377 grams; p<0.0001), which are both statistically significant.Treatment with S. typhimurium and Salmonella-pIL2 results in a reductionin tumor burden (63 and 84%, respectively) in animals withretroperitoneal neuroblastoma.

Prevention and Treatment of Pulmonary Metastases in Murine Osteosarcoma.

Brent S. Sorenson, Kaysie L. Banton, Natalie L. Frykman, Arnold S.Leonard, Daniel A. Saltzman, “Attenuated Salmonella typhimurium withInterleukin 2 Gene Prevents the Establishment of Pulmonary Metastases ina Model of Osteosarcoma,” Journal of Pediatric Surgery (2008) 43,1153-1158; “Attenuated Salmonella typhimurium with IL-2 Gene ReducesPulmonary Metastases in Murine Osteosarcoma,” Clin Orthop Relat Res(2008) 466:1285-1291.

Osteosarcoma is the most common primary bone cancer, with approximately900 new cases annually in the United States. There is a peak incidencein early adolescence correlated with pubertal bone growth and a secondpeak after age 50. Primary tumors develop in the distal femur andproximal tibia and humerus. Current management of primary osteosarcomainvolves surgical resection with wide margins or limb amputation inconjunction with pre- and postoperative neoadjuvant chemotherapy.Survival from local disease has improved from 20% in 1970 toapproximately 70% at 3 years with the advent of current treatment withhigh-dose methotrexate, cisplatin, ifosfamide, and doxorubicin. Despitethe dramatic enhancement in patients' event free survival, toxicityaffects nearly all patients treated with these therapies. However, inpatients who present with metastatic disease detectable by CT, less than30% disease-free survival has been achieved. In some cases, intravenousinterleukin-2 treatment has resulted in complete regression of theprimary tumor, though severe side effects have been noted, includingfever, nausea, capillary leak syndrome, and death.

We demonstrated a single oral dose of an attenuated Salmonellatyphimurium genetically engineered with a gene for a truncated humaninterleukin-2 (SalpIL2) substantially reduces unresectableadenocarcinoma metastases to the liver in experimental treatment andprophylactic mouse models. In addition, SalpIL2 reduces the volume andmass of retroperitoneal neuroblastoma tumors in an experimental murinetreatment model. Interestingly, the Salmonella species of bacteria alsohave a unique propensity to colonize tumor cells. In vitro experimentshave demonstrated the ability of SalpIL2 to invade and dividepreferentially within K7M2 osteosarcoma cells with respect to primarymurine hepatocytes. Thus SalpIL2 may be able to persist for long periodsin malignant tissues providing a prolonged antigen presentation stateand enhanced immune response in the region.

Based on our previous observations, we hypothesize SalpIL2 wouldsubstantially reduce osteosarcoma pulmonary metastases by increasingsplenic and local NK cell populations in this newly developedexperimental model.

Materials and Methods

1. Reduction of Pulmonary Metastases after Injection with MurineOsteosarcoma Cells.

In triplicate experiments, 45 balb/c mice were administered murine K7M2osteosarcoma cells by tail vein injection. Three days later, animalswere orally gavaged saline or attenuated Salmonella species; they werethen euthanized on day 21 for tumor enumeration, volume, and assessmentof systemic NK and T cell populations. In an additional experiment,animals were harvested for pulmonary lymphocyte analysis.

Attenuated S. typhimurium v4550 and plasmid pYA292 were a gift from Dr.Roy Curtiss III, Washington University, St. Louis, Mo. v4550 wasattenuated by Tn10 transposon mutagenesis to remove adenylate cyclase(cya), cyclin adenosine monophosphate receptor protein (crp), andaspartate semialdehyde dehydrogenase (asd) genes from the bacterialgenome. These mutants have virulence factors removed, but retainimmunogenic properties. Plasmid constructs with and without thetruncated gene for human interleukin-2 (SalpIL2) were electroporatedinto v4550 using well-described techniques and renamed SalpIL2 andSal-NG [28]. Standardized glycerol stocks of approximately 10⁸ CFU/mLwere prepared by creating growth curves for overnight cultures in Luriabroth (Difco Laboratories, Detroit, Mich.) and freezing aliquots with anO.D.₆₀₀ of 0.160 in liquid nitrogen. For experiments, cryovials werethawed to room temperature, serially diluted, and plated on MacConkeyagar plates to verify CFU concentration. Use of S. typhimurium with agene for a truncated human interleukin-2 was approved by the Universityof Minnesota Institutional Biosafety Committee (numbers 541 and 542).

Female balb/c mice 6 to 8 weeks old were acquired from Harlan SpragueDawley (Indianapolis, Ind.) and housed in microisolator cages, fedstandard mouse chow and water ad libitum, and given 12 hours light/darkcycles under the strict care of the University of Minnesota ResearchAnimal Resources.

The murine osteosarcoma cell line K7M2 was acquired from the AmericanType Culture Collection and maintained in 25 mL DMEM, 10% fetal bovineserum, 1% penicillin, streptomycin, and L-glutamine (Sigma Chemical, St.Louis, Mo.) at 37° C. at 5% CO₂. Media was changed twice weekly andcells were not allowed to become confluent. Tumor cells were incubatedwith 0.3% trypsin EDTA (Invitrogen, Carlsbad, Calif.) at 37° C. at 5%CO₂ for 3 minutes or until nonadherent. Cells were serially washed inHanks' balanced salt solution (HBSS, Invitrogen) before enumeration viatrypan blue exclusion (Sigma Chemical) on a phase contrast hemocytometer(Hausser Scientific, Horsham, Pa.). The suspension was diluted to aconcentration of 2×10⁶ cells per mL and placed on ice prior toinjection. All tumor preparations were more than 90% viable and usedwithin 1 hour of preparation.

We developed a model for pulmonary metastases for these experiments.Similar techniques have been implemented for quantifying the metastaticpotential of the K7M2 cell line. In triplicate experiments, animals wereanesthetized by intraperitoneal injection of 2:1 xylazine 20 mg/mL(Phoenix Pharmaceuticals, St. Joseph, Mo.) and ketamine 100 mg/mL (AbbotLaboratories, North Chicago, Ill.). The animals' eyes were swabbed withBetadine ophthalmic eye ointment (Purdue Pharma LP, Stamford, Conn.) andthe animals were placed in a Broome odent Holder (Kent Scientific,Torrington, Conn.). Tails were incubated for one minute in 47° C.Betadine solution (Purdue Pharma LP) to allow for vasodilatation of theleft lateral tail vein and scrubbed with a 70% ethanol swab before200,000 K7M2 cells were injected into the left lateral tail vein. Micewere placed at random in cages with microisolators and placed on awarming pad for 2 hours or until animals were walking. On Day 3, micewere orally gavaged with their respective treatments (n=5), 200 μL HBSSfor controls or 3×10⁷ CFU of either Sal-NG or SalpfL2. In allexperiments the mice were evaluated for presence of metastases 3 weeksafter injection by euthanasia followed by an intratracheal injection of1.5 mL of 15% India-ink solution via a blunt-ended needle. The stainedlungs were carefully resected and rinsed in Fekete's solution (300 mL70% ethanol, 30 mL 37% formaldehyde, 5 mL glacial acetic acid) and thenplaced in fresh Fekete's solution overnight in a 60×15 mm tissue culturedish. Tumors were enumerated, their diameters were measured and volumewas calculated by 4/3πr³, assuming the metastases were spherical.Spleens were aseptically removed and placed in 60×15 mm culture dishesfor FACS analysis of splenic lymphocytes. Due to inability to collectpulmonary lymphocytes or perform histopathological analysis from Feketestained lungs, two additional experiments with 25 mice were conducted.Lungs for histopathological analysis were aseptically removed and placedin 10% formalin and sent to the University of Minnesota'sHistopathological Core for slide preparation.

Spleens and lungs for FACS analysis were incubated with 37° C. DMEMcontaining 10% fetal goat serum and crushed with sterile glass stoppers.Homogenates were filtered through a 150-1m nitex mesh (Sefar American,Kansas City, Mo.) and transferred onto 5-mL lymphocyte separation medium(Ficol, Mediatech Inc., Hendon, Va.). The cell suspension wascentrifuged for 1 hour and the lymphocyte layer was carefully collected.Cells were serially washed with PBS with 1% bovine serum albumin (BSA)and 0.1% NaN3 (Sigma Chemical) and split for monoclonal antibodystaining. Cells were stained with DX5/CD 49a PE and CD 3 FITC for NKcell analysis and CD 8 PerCp and CD4 FITC (Phaminogen, San Diego,Calif.) for T lymphocyte populations. Cells were cold incubated for 30minutes at 4° C. before a final wash with PSB/BSA/NaN3 and stored underfoil at 4° C. until FACS analysis. Splenic and pulmonary lymphocytescollected from experimental mice were analyzed with a FACScalibur(Becton Dickenson, Grenoble, France) and analyzed with Cell Quest ProSoftware (Becton Dickenson, San Jose, Calif.). Lymphocyte populationswere identified using forward-scatter versus side-scatter profiles andgated for mononuclear lymphocytes. Natural killer cell populations thenwere identified by DX5/CD 49b⁺/Cd 3⁻, T_(H) and T_(C) cells by singlepositive populations based on 10,000 gated events.

Number of tumors, volume, and lymphocyte populations were entered foreach mouse at the experimental endpoint to calculate the total meanvalues for each treatment group. All differences between two groups weredetermined by Fisher's exact test. Graphs were constructed usingMicro-soft Excel (Microsoft, Redmond, Wash.). Statistical tests wereperformed using StatView software v. 5.0.1 (SAS Institute, Cary, N.C.)

Results

Attenuated S. typhimurium with and without a gene for truncated humaninterleukin-2 (SEQ ID NO: 1) had fewer total tumors (20.93 and 33,respectively; p<0.0175 and 0.0006, respectively) compared to salinecontrols (58.42) (FIG. 20). SalpIL2 reduced (p<0.0037) overall volume ofpulmonary metastatic nodules by 78% with respect to saline controls.There was no discernable difference in the reduction of tumor number andvolume between the two Salmonella treatments. NK cell populationsincreased (p<0.0163 and p<0.0407, respectively) in Sal-NG- andSalpIL2-treated groups (18.5% and 16.8%, respectively) with respect tosaline controls (8.6). Cytotoxic T lymphocyte populations were notnoticeably affected by oral administration of Sal-NG and SalpIL2(p=0.270 and p=0.237) compared to saline controls. T helper cellpopulations were reduced in the SalpIL2 group (14.3%; p<0.0077) comparedto saline controls (20.7%). Local pulmonary lymphocytes collected wereelevated in SalpIL2 compared to control and Sal-NG treated animals(p<0.0196 and p<0.0070 respectively). Gross examination of the harvestedpulmonary tissues demonstrate the reduction in the mean number ofmetastatic tumors by SalpIL2 with respect to saline controls.Histological analysis of the tissues treated with SalpIL2 show adecreased invasion of the metastases into the subpleural space and anincrease of mononuclear cells in the area.

2. Prevention of Pulmonary Metastases by Administration of SalpIL2Before Injection with Murine Osteosarcoma Cells.

Seven days before tumor injection, mice were orally gavaged with theirrespective treatments (n=5), 200 μL Hanks' balanced salt solution forcontrols or 3×107 CFU of either Sal-NG or SalpIL2. Previously, weestablished a treatment model for pulmonary metastases to examine theantitumor mechanisms of SalpIL2. In triplicate experiments, animals wereanesthetized by intraperitoneal injection of 2:1 xylazine, 20 mg/mL(Phoenix Pharmaceuticals, St Joseph, Mo.), and ketamine, 100 mg/mL(Abbot Laboratories, North Chicago, Ill.). On day 0, animals wereprepared and administered 2×105 K7M2 mouse OS cells using well-describedtechniques. Mice were selected at random from their respective groupsfor IV tail vein injection. In all experiments, the mice were evaluatedfor presence of metastases 3 weeks postinjection by euthanasia followedby an intratracheal injection of 1.5 mL of 15% India ink solution via ablunt-ended needle. The stained lungs were carefully resected and rinsedin Feket's solution overnight. Tumors were enumerated and classified bythe diameter of the nodules; volume was calculated by 4/3πr³, assumingthe metastases were a sphere. Spleens were aseptically removed andplaced in 60×15-mm culture dishes for fluorescent-activated cell sorting(FACS) analysis of splenic lymphocytes.

Splenic Lymphocyte Preparation

Splenic lymphocytes were isolated by mechanically mincing spleens inDMEM containing 10% fetal goat serum. Splenic homogenates were filteredthrough a 150-μm nitex mesh (Sefar American, Kansas City, Mo.) andseparated using density gradient centrifugation in lymphocyte separationmedium (Ficol, Mediatech Inc, Hendon, Va.). Cells were serially washedwith phosphate buffered saline (PBS) with 1% bovine serum albumin.

Fluorescent-Activated Cell Sorting

Splenic lymphocytes collected from experimental mice were analyzed witha FACSCalibur (Becton Dickenson, Grenoble, France) and analyzed withCell Quest Pro software (Becton Dickenson, San Jose, Calif.). Lymphocytepopulations were identified using forward scatter vs side scatterprofiles and gated for mononuclear lymphocytes. Natural killer cellpopulations then were identified by DX5/CD 49b⁺/Cd 3 ⁻, T_(H), and TCcells by single positive populations based on 10,000 gated events.

Statistical Analysis

Data for tumor number, volume, and splenic lymphocytes were evaluated byanalysis of variance and Fisher's Exact test using Statview statisticalanalysis software V 5.0.1 (SAS Institute, Cary, N.C.). Graphs and chartswere constructed using Microsoft Excel (Microsoft, Redmond, Wash.).

Saline control and SalpI12 treated tissues grossly determined to berepresentative samples of the mean number of tumors present per groupwere photographed. Pretreatment with attenuated SalpIL2 and Sal-NGsignificantly reduced the number of pulmonary metastases (42.87 and62.69, respectively) with respect to saline controls (183.82; P<0.0001),representing a 77% reduction in tumor. More important, tumor volume wasreduced to 49.19 mm³ and 58.13 mm³ by SalpIL2 and Sal-NG as compared to318.02 mm³ in saline controls (P<0.0001). Furthermore, splenic NK cellpopulations were increased 396% with SalpIL-2 (11.25%; P<0.0007) and426% with Sal-NG (12.76%; P<0.0003) compared to saline treated groups(2.84%). CD 8+T lymphocyte populations were unaffected by prophylaxiswith SalpIL2 and Sal-NG. However, CD4+ T cells were significantlydecreased at the time of animal sacrifice in SalpIL2-treated andSal-NG-treated groups (11.58 and 11.46, respectively) as compared tosaline controls (14.80; P<0.0193 and P<0.0187, respectively).

Salmonella typhimurium is a facultative intracellular organism thatpreferentially tracks to and divides in OS in vitro and reduces tumorburden in a prophylactic model of OS pulmonary metastasis. SalpIL2 wasdesigned to produce a synthetic truncated IL-2, natively a 15-kDacytokine produced by activated CD4+ T cells as well as other immunecells and is involved in the activation and proliferation of NK cellsand T lymphocytes. The IV administration of IL-2 has been associatedwith severe side effects including fever, fatigue, malaise, andcapillary leak syndrome. Numerous attempts have been made to limit thedose-dependent toxicity of IL-2 by altering the route, method, andfrequency of dosing. Incorporation of IL-2 into liposomes, single ormultilayered lipid vesicles, has resulted in a time-release of solubleeffector compounds effecting the drug's toxicity and efficacy. In oneclinical study, a liposomal preparation of IL-2 reduced IL-2 toxicitycompared to soluble IL-2. In preclinical trials, liposomal IL-2 wasshown to be effective in reducing pulmonary OS metastases in canines.Our laboratory has attempted to establish a local delivery system forIL-2 that may diminish the common side effects associated with IVdelivery, by genetically engineering an attenuated strain of S.typhimurium to act as a biologic vector for a truncated human IL-2 gene.Other investigators have attempted the use of other strains ofattenuated S. typhimurium for antitumor therapy, with limited successwhen given intravenously. Oral administration of SalpIL2 allows thebacteria to follow the natural route of infection and colonize varioustissues including the Peyer's patches, liver, lung, and spleen.

We developed our prophylactic models based on the NK cell response afteroral administration of SalpIL2. We found the peak NK cell response onday 14 postgavage; thus, tumor cells implanting on day 7 will encounterthe highest rate of NK cell proliferation during the infection ofSalpIL2. In our prophylactic model, a more dramatic reduction in tumorvolume was observed than in our previous treatment model of metastaticOS. Tumor volume was reduced more than 6-fold with SalpIL2 prophylaxiswith respect to saline controls. This model represents the subset ofpatients who do not present with radiologic detectable pulmonarymetastases; however, because 80% of patients develop metastatic disease,all patients are thought to have some degree of micrometastases at timeof diagnosis. Prophylaxis with SalpIL2 in our model increases systemicNK cells nearly 400% compared to saline-treated animals. Interestingly,we were unable to detect a significant difference between either of theSalmonella strains. Previously, we reported that a single oral dose ofSalpIL2 significantly increased pulmonary and splenic NK cells in amurine model of OS. In both our treatment and prevention models, we werealso unable to detect significant differences in splenic NK or CD 8+T-cell populations but did find a significant increase of local NK cellsin the SalpIL2 group with respect to saline and Sal-NG in the treatmentmodel animals. The presence of an increased local NK cell populationsuggests functionality of the recombinant IL-2 locally within thepulmonary tissue; however, the fate of the recombinant IL-2 is currentlyunknown. Additional experiments are necessary to investigate thelocation of the recombinant IL-2 and whether acute and chronicinfections with SalpIL2 produce IL-2 associated toxicities.

Tumors were injected during a peak of an immune response to bacterialinfection resulting in a more circulating activated NK cells,prohibiting OS tumor implantation into pulmonary tissue and enhancingtumor surveillance. Immune tumor surveillance is one theory of tumordevelopment; tumors are constantly originating while circulating immunecells, primarily NK cells and cytotoxic T cells provide protectionagainst malignant disease. Depression of the immune system thereforeallows tumor cells the ability to escape surveillance and progress toclinical disease. Increasing NK cells may lead to increased interactionbetween NK and tumor cells, thus inhibiting of cellular invasion andimplantation into distant sites. Tumors that do establish as pulmonarymetastases are subjected to local inflammatory response to SalpIL2.

Survival for OS has not progressed since the implementation of adjuvantchemotherapy for primary tumors nearly 4 decades ago. Combinationtherapy has not been shown to be effective in prevention of OS pulmonarymetastases. Although the 5-year survival for patients who presentwithout pulmonary metastases has reached 70%, there has been littlebenefit in the long-term survival of patients who present with pulmonarymetastases. Attenuated S. typhimurium strains may be a viable biologicaldelivery vector for the treatment and prevention of metastatic OS.

Proposed Theory/Mechanism

The exact mechanism responsible for the improved colorectal cancerresponse resulting from the administration of S. typhimurium χ4550pIL2concurrently with highly potent antioxidant oils is not yet known. Wehave shown that S. typhimurium χ4550pIL2 alone increases the populationsof host effectors cells (NK cells and CD8+ Cytotoxic T cells. Further,it has long been known that both NK cells and CD8⁺ lymphocytes play animportant role in the destruction of tumor cells both in vitro and invivo.

Oxidative stress is thought to play an important role in thepathogenesis of numerous chronic diseases, such as coronary heartdisease and cancer. Although there are many factors in the developmentof theses diseases, considerable experimental evidence has linked theproduction of free radicals to biological damage that can provide abasis for the initiation and progression of certain diseases. Freeradicals are atoms or molecules that are highly reactive with othercellular structures due to an unpaired electron. Consequently, they arecapable of chemically altering nearly all major classes of biomolecules(e.g., lipids, nucleic acids and proteins). Free radicals such as thesuperoxide anion, the hydroxyl radical and singlet oxygen can beproduced in vivo by factors such as dietary imbalances, tobacco smoke,pollutants or from sources such as lipid peroxidation, inflammation andbiochemical reactions. They are capable of damaging DNA, inhibiting itsrepair and amplifying viral and oncogene expression. Interestingly, freeradicals are also generated by cells of the immune system to destroyinvading organisms. However, the presence of these strong oxidantsplaces additional stress on the immune system, which can result in adiminished response against invaders. Furthermore, the long-termpresence of these oxidizing species will eventually be detrimental tothe human body.

Humans and other aerobic organisms have evolved a variety of mechanismsto protect themselves from the deleterious effects of free radicals.These defense mechanisms protect against free radical damage eitherdirectly or indirectly. The defense mechanisms include enzymes such ascatalase and superoxide dismutases and repair enzymes such as DNAglycosylases. Water and lipid-soluble antioxidants such as ascorbate(vitamin C), {acute over (α)}-tocopherol (vitamin E) and beta carotenealso act to eliminate free radicals. These antioxidants help shield DNAfrom the deleterious effects of oxidative damage by absorbing unstableoxygen molecules.

A number of sources indicate a relationship between diet and cancerincidence in humans. The geographic distribution of types of cancer, thechanging cancer patters and data from experimental animal studies allindicate that diet and nutrition are important factors in the controland prevention of human cancers. The potential importance of diet incancer prevention is also noted by the suspected causes of some cancers.Most cancers (an estimated 80% to 90%) have environmental causes and aretherefore potentially preventable. Much controversy surrounds the actualpercent of cancers associated with dietary factors, but it has beenestimated that in men 30% to 40% of all cancers are in some way relatedto diet. In women, it is believed that 60% of all cancers are related todiet. Another study estimates that 35% of cancer is diet related.Regardless of the exact numbers, these are impressive percentages.

Presumably, pathology due to oxidative stress results when thegeneration of free radicals exceeds the cell's capacity to protect orrepair itself. Therefore, if oxidative damage is an important etiologicfactor in the pathogenesis of diseases such as cancer, then it followsthat antioxidants, which act to reduce oxidative stress, may play a rolein the prevention or treatment of these diseases. The accumulation andgrowth of free radicals in tissues is often found in association withsuppressed immune function, infections such as HPV and HIV, cancer andheart disease. In fact damage to heart blood vessels and the incidenceof coronary heart disease has been shown to be reduced with increaseddietary antioxidant intake. The protective effects of topicalantioxidants (vitamin A derivatives such as retinoic acids) againstproliferative dermatological diseases as well as photo-aging have beenwell documented. Many studies continue to demonstrate below normalantioxidant tissue and blood plasma levels in women with HPV and othercervical neoplasms, while high levels provide protection against theirinitiation and progression.

Like the B vitamins, the beneficial effects of antioxidants are mostnotable when combined with one another. In fact, diets high inantioxidants (e.g., the traditional Greek Mediterranean diet) have beenshown to be protective against cancer and various diseases. It isbelieved that antioxidants alter cancer incidence and growth by actingas anticarcinogens. Nutritional anticarcinogens function by (a)inhibition of tumor initiation via alteration of cellular metabolism,(b) picking up active forms of carcinogens and preventing them fromreaching target sites, (c) alteration of the body's defense systems, (d)inhibition of cancer progression once it has been initiated by thealteration of cell differentiation, and (e) prevention of geneactivation and cellular proliferation by tumor promoters.

It is also known that in individuals, and in entire populations, showingthe lowest rates of colorectal cancer occur when diets rich in fruitsand vegetables are consumed. One possible mechanism for this phenomenonis that fruits and vegetables contain anticarcinogens, such asantioxidants, that prevent the development of colorectal tumors. It isbelieved that antioxidants may inhibit the process of lipid peroxidationand reduce the formation of mutagenic peroxidation products in thecolon. It is hypothesized that specific receptor populations for NKcells and CD8+ Cytotoxic T cells are increased by the administration ofan effective amount of S. typhimurium χ4550pIL2 together with highlypotent antioxidant oils, such as black raspberry oil. An alternativehypothesis suggests that the administration of an effective amount of S.typhimurium χ4550pIL2 together with highly potent antioxidant oils, suchas black raspberry oil somehow sends a signal to the cellular geneticmachinery to increase the number of receptors and/or cell populationsthemselves.

It is believed that the administration of S. typhimurium χ4550pIL2concurrently with highly potent antioxidant oils will also be effectivein treating infectious disease, other cancerous tumors, slowing theageing process and treating other immuno-compromised states, includingHIV infections. An additional use of the present invention would beadministering it to cancer patients between periods of chemotherapyand/or radiation treatments. It is further believed that the compositioncontaining S. typhimurium χ4550pIL2 concurrently with highly potentantioxidant oils will also be effective as a preventive treatment whenused in patients with high risk factors for colon cancer such as familyor behavioral history.

Use

Prior to the oral delivery of the S. typhimurium χ4550pIL2 andanti-oxidant oil alkalization of the patient's stomach is necessary toneutralize gastric acid to prevent the acid induced destruction of theS. typhimurium χ4550pIL2. This is accomplished by orally administering30 ml of Bicitra® 15 minutes prior to administering the S. typhimuriumχ4550pIL2 with anti-oxidant oil. A dose containing approximately 10⁶ to10⁸ S. typhimurium χ4550pIL2 is administered to a human patient once, atthe initiation of treatment. Approximately one-half teaspoon of coldpressed black raspberry oil is administered to the patient twice a day,throughout the treatment period. As treatment continues, the dosage ofeach may be escalated or altered as indicated.

While the above description of use of the present invention isspecifically directed to human beings, it is also speculated that thepresent invention would also be effective in treating agricultural(e.g., cattle, swine, sheep, horses, domesticated fowl) and companion(dogs, cats, birds) animals.

Although the present invention has been described in considerable detailwith reference to certain preferred versions thereof, other versions arealso possible. Therefore, the spirit and scope of the appended claimsshould not be limited to the description of the preferred versionscontained herein.

Proposed Human Clinical Trial (Phase 1)

The following has been submitted to the U.S. Department of Health andHuman Services, Food and Drug Administration, in an Investigational NewDrug Application (IND) for “Salmonella typhimurium Expressing IL-2 Gene,Attentuated; Administered Orally.” Clinical hold has been removed andpermission has been granted to proceed with the study.

SCHEMA

Dose Escalation Schedule Dose Level Dose of Salmonella (number) Level 110⁵ Level 2 10⁶ Level 3 10⁷ Level 4 10⁸ Level 5 10⁹

1. Objectives

1.1 Assess the safety of oral administration of an attenuated strain ofsalmonella typhimurium expressing IL-2 in patients with cancermetastatic to the liver.1.2 Assess the in vivo production of IL-2 and its effect on immunefunction.1.3 Assess the length of colonization and excretion with the modifiedbacterium.

2. Background 2.1 Rationale

IL-2, a 15-kilodalton cytokine, is produced by activated CD4+T cells. Itpromotes lymphocyte proliferation and enhances the cytolytic function ofT cells and NK cells.3,4 The ability of IL-2 to facilitate cytolyticactivity in lymphocytes and to induce the lymphokine-activated killer(LAK) phenomenon with subsequent malignant cell destruction has resultedin decades of studies of IL-2-based immunotherapy.5,6 With and withoutadoptively transferred IL-2 activated cells, IL-2 has been effective inmurine tumor models and in a limited number of human patients withmalignancies, including renal cell carcinoma and melanoma.7-9 However,high doses of IL-2 have resulted in severe toxicity in many patients,thereby limiting its use. Major toxicities associated with high-doseIL-2 administration include malaise, fever, anasarca, jaundice, renaldysfunction, and capillary leak syndrome.1^(0,11)

Investigators have attempted to diminish the adverse effects ofsystemically administered IL-2 by altering the dose, schedule, route,and rate of infusion; however, the toxic effects of IL-2 therapy havepersisted to some degree.³⁻¹¹ Local delivery of IL-2 may produce lesstoxicity.⁴ IL-2 liposomes reportedly modify the pulmonary toxicity ofIL-2 by altering the absorption and distribution of the entrappeddrug.¹¹ Thus, local effects achieved with a depot preparation of IL-2improved the therapeutic index.

Salmonella are gram-negative facultative intracellular organisms thatcan cause a wide spectrum of disease in both humans and animals. Afteroral administration, Salmonella penetrate into the Peyer's patches ofthe intestine, where they can be phagocytosed by the residentmacrophages and then carried through the reticular endothelial systembefore finding a safe site within the liver and spleen.¹² In addition,Salmonella may be disseminated systemically within the localmacrophages, which subsequently induce humoral and cellular immuneresponses.¹³ An alternatative mechanism of invasion has been describedwhere Salmonella are engulfed by dendritic cells at the mucosal surfaceand then transported from the gastrointestinal tract to the bloodstreamby macrophages.¹⁴ Unlike other invasive bacteria, Salmonella can resideand divide within macrophages, the antigen-presenting cell. Peptidesresulting from bacterial degradation are packaged, bound to the majorhistocompatibility complex (MHC) class II molecules, and presented toCD4+ T cells. In addition, antigen-specific cytotoxic CD8+ T cellsagainst proteins expressed by the Salmonella carriers can also bestimulated. This cytotoxic response appears to take place through analternative MHC class I processing pathway. ¹⁴

Capitalizing on the unique ability of this organism to invade hosttissue and trigger a local as well as systemic immune response,researchers theorized that attenuation of Salmonella could preservetheir abilities of invasion and immune stimulation while amelioratingtheir deleterious effects.¹⁵ Attenuation of Salmonella has been achievedby several methods. In human trials, chemical attenuation of Salmonellatyphi conferred both local and systemic humoral and cellular immunitywith a significant but incomplete protection against typhoid fever.¹⁶Subsequently, several attenuated strains of both S. typhi and S.typhimurium were developed by deleting 2 genes encoding essentialenzymes in the biosynthesis of aromatic compounds (aroA) and adenine(purA). These attenuated bacteria were well-tolerated but not asimmunogenic, leading to the developments of these auxotrophic strains.Although auxotrophic strains were more immunogenic, transient bacteremiawas seen in human volunteers.¹⁵ Curtiss et al. were primarilyresponsible for developing attenuated strains of Salmonella that lackthe genes encoding the adenylate cyclase (cya) and cyclic adenylatecyclase (crp) receptors. These bacteria were found to be highlyimmunogenic and safe in human volunteers, with 80% to 100% of whomdemonstrated seroconversion to bacterial antigens.¹⁷⁻¹⁹

Attenuated Salmonella species are effective vaccine carriers. Examplesinclude attenuated S. typhimurium vaccines for murine listeriosis andthe human papillomavirus type 16.²⁰ In addition, S. typhimurium speciesappear to have the unique propensity to track to tumor cells, andclinical trials have been initiated using an intravenous injection of anattenuated form of S. typhimurium, lacking aroC, in human patients withwidespread malignancies.^(21,22) In animal studies, attenuatedSalmonella as anti-cancer agents have been primarily used in mousemodels, using various routes of delivery: oral or injected, eitherintratumoral or intravenous. One study focused on the antitumorpotential in mice with intravenous injection of attenuated Salmonella totreat a multitude of tumor types that were subcutaneously implanted:Salmonella accumulated in tumors more readily than in the normal liverreservoir; despite partial inhibition of tumor growth, ultimatelyprogressive growth was observed for all tumor types.²⁴

Characterization of the Salmonella pathogenicity island (SPI) genesrevealed that one cluster, the SPI-1 genes, promote invasion from theintestine, while another cluster, the SPI-2 genes, support systemicsurvival within macrophages and other cells. In a subcutaneous melanomamodel, SPI-2 genes appeared to be essential for tumor growthsuppression.²³

There have been numerous studies examining the immune effectiveness ofSalmonella vaccines for various entities in human volunteers. Theresults have been mixed—some studies documented an immune response to aparticular foreign antigen, while others did not. Most researchersspeculate that this mixed response results from the method ofattenuation for the particular strain of Salmonella used, the type ofadjuvant used, the foreign protein being expressed, or the route ofadministration of the Salmonella. Clinical experience with Salmonella totreat malignancies has been sparse. To date, 2 clinical studies haveused Salmonella for cancer treatment.^(21,22) The first involvedpatients with metastatic malignant melanoma and metastatic renal cellcarcinoma. These patients received intravenous attenuated Salmonella ona dose escalation schedule of 10⁶ to 10⁹ bacteria administered over a4-hour interval. They all appeared to tolerate intravenous infusion ofthe bacteria, and some of them had tumor colonization by the bacteria>But, only 1 patient demonstrated a complete response and was free oftumor 3 months after infusion. The remaining patients all hadprogression of disease. Interestingly, most patients demonstrated adose-related increase of the proinflammatory cytokines interleukin-1(IL-1), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), andinterleukin-12 (IL-12). In addition, most of these patients alsodeveloped strain-specific IgG and IgM antibodies.

In contrast to intravenously administered Salmonella, the second trialused an intratumoral injection of attenuated Salmonella expressing theEscherichia coli cytosine deaminase gene with concomitantly administered5-fluorocytosine.³² This intratumoral study included 3 patients withvarious tumor types. All 3 converted 5-fluorocytosine to 5-fluorouracil,yet disease progression persisted; 1 patient had to be removed from thestudy because of the development of significant toxicities.

2.2 Study Agent: Attenuated Salmonella typhimurium Containing the Genefor Human IL-2 (Salmonella χ4550(pIL-2))

In contrast to the Salmonella used in these 2 clinical trials, wepropose ORAL administration of the bacteria. The use of live attenuatedSalmonella as IL-2 carriers has been investigated for several reasons.First, Salmonella naturally colonizes the gut-associated lymphoid tissue(GALT), liver, and spleen.¹² Second, colonization of the liver andspleen initiates a generalized cellular immune response against thebacteria and can also induce a carrier state. In addition, attenuatedSalmonella have been shown to preferentially invade various subcutaneoustumors more readily than liver tissue, at tumor-to-liver ratios rangingfrom 250:1 to 9000:1.²⁵

We have used the χ4550 strain of S. typhimurium as our parental strain.It lacks the enzyme aspartate semialdehyde dehydrogenase (asd), which iscontained in the pYA292 plasmid. Bacteria that lack asd cannot makediaminopimelic acid (DAP), an essential component of the bacterial cellwall, and cannot survive unless they carry a plasmid with the asd geneor unless DAP is provided in the growth media. We have also modified thepYA292 plasmid, which contains the asd gene, and is therefore capable ofrescuing χ4550 S. typhimurium, by incorporating the gene for human IL-2(pIL2). Thus, we have 2 strains of attenuated S. typhimurium that havebeen transformed either with the empty pYA292 plasmid (hereafterreferred to as attenuated Salmonella lacking the IL-2 gene[Salmonella-no-IL2]), or attenuated Salmonella with the pIL2 plasmid(hereafter referred to as: attenuated Salmonella containing the IL-2gene [Salmonella-IL2]). Because the loss of the IL-2-containing pYA292plasmid (pIL2) would also result in the loss of the plasmid-encoded asd,we have achieved stable expression of human IL-2.

We have submitted an Investigational New Drug (ND) application to theU.S. Food and Drug Administration (FDA) and are in the process ofresponding to the request for more information. If our IND is approved,we plan to conduct a Phase I clinical trial using ORALLYADMINISTERED_attenuated Salmonella-IL2 for patients with unresectablehepatic metastases from any gastrointestinal malignancy.

Preliminary Studies

Our research laboratory has extensive experience with attenuatedSalmonella-IL2 for unresectable adenocarcinomatous liver metastases,osteogenic sarcomatous lung metastases, and primary neuroblastoma.²⁶⁻³¹A brief summary of our findings follows:

IL-2 produced by Salmonella-IL2 is biologically active. We studiedmurine splenocyte NK function as an indicator of in vivo IL-2 biologicactivity. We conducted duplicate experiments in which C57BL/6 mice wererandomly divided into 3 groups. We grew suspensions of Salmonella-IL2,which exhibited the high IL-2 production to 10¹⁰ CFU/ml; then gavage fed10⁹ CFU in 0.25 mL to the first group. We used a suspension of 10⁹ CFUin 0.25 mL of the attenuated Salmonella-no-IL2 as a negative control togavage the second group, and saline to gavage the third group. On days 3and 7 after gavage, we isolated splenic mononuclear cells using a Ficolldensity sedimentation gradient. Interface mononuclear cells were used aseffector cells in a 4-hour ⁵¹Cr release cytotoxicity assay againstNK-sensitive YAC-1 lymphoma cells. We found that the splenocytes of micegavage-fed Salmonella-IL2 had significantly increased splenocyte NKactivity on days 3 and 7 after gavage, as compared with mice gavage-fedeither saline or Salmonella-no-IL2. Our findings on day 3 (Table 1) andday 7 (data not shown) did not differ significantly and strongly suggestthat the IL-2 produced by Salmonella-IL2 was biologically active.

TABLE 1 Day 3 Effectors Murine Splenocytes % Cytotoxicity Control 15.0%± 6.3 Salmonella-no-IL2 17.3% ± 4.7 Salmonella-IL2 30.5% ± 6.7

Attenuated Salmonella-IL2 Suppresses In Vivo Tumor Metastases.

We evaluated the in vivo antitumor efficacy of Salmonella-IL2, usingmurine MCA-38 adenocarcinoma hepatic metastases generated in C57BL/6mice. Our experimental design was based on the Rosenberg model of murineadenocarcinomatous liver metastases; briefly, it consists of performingan intrasplenic injection of 2×10⁵ MCA-38 adenocarcinomatous cells thatultimately result in liver metastases.²⁴ We divided mice into 3 groups,3 days after tumor inoculation and gavage-fed them a single oral dose of(1) saline, (2) Salmonella-no-IL2, or (3) Salmonella-IL2. We enumeratedsurface metastatic deposits 14 days after tumor inoculation. As shown inFIG. 21, we found a significant reduction in the number of livermetastases in the Salmonella-IL2 group, as compared with either thecontrol group or the Salmonella-no-IL2 group.

NK Cells and CD8⁺T Cells are the Major Mediators of the AntitumorResponse Elicited by Salmonella-IL2.

Our observation that Salmonella-no-IL2 did not demonstrate an antitumoreffect led us to surmise that cytokines produced by the host in responseto Salmonella colonization alone does not appear to cause theseantitumor effects. We sought to determine which host effector cellpopulation was responsible for the antitumor effect seen withSalmonella-IL2. Since IL-2 directly enhances antitumor cytolyticfunction of NK cells, macrophages, and T cells and promotes lymphocyteproliferation, any of these cellular mechanisms could contribute to thesignificant reduction of liver metastases seen with Salmonella-IL2. Weused our standardized treatment model of liver metastases in 4 cohortsof mice (1) untreated control mice gavage-fed saline, (2) untreatedcontrol mice gavage-fed saline and depleted of a particular hosteffector cell population, (3) treated mice gavage-fed Salmonella-IL2,and (4) treated mice gavage-fed Salmonella-IL2 and depleted of aparticular host effector cell population. Specific host effector cellpopulations that were depleted included NK cells, CD8+ cells, CD4+cells, and liver Kupffer cells. We found that the number of livermetastases was reduced in mice that had been treated withSalmonella-IL2, as compared with control mice treated with saline. Thiseffect was abrogated in mice in which either the NK or the CD8+ effectorcells were depleted, but not in mice in which either the CD4+ effectorcells or liver Kupffer cells were depleted (FIG. 2). This difference isnot surprising because both NK cells and CD8+ cells are known togenerate direct tumor destruction. IL-2 markedly potentiates NK cellcytolytic activity against tumor cell targets through the secretion ofcytolytic molecules such as perforin and the granzymes. NK cells killtheir targets in an MHC unrestricted fashion, while CD8+ cells requirethe expression of MHC class I by the tumor for effective recognition andkilling to take place. CD4+ cells are usually not cytolytic, but havebeen shown to kill MHC class II tumor targets. Because the tumor used inthese studies, MCA-38, does not express MHC class II, it is notsurprising that depletion of the CD4+ cell subset did not affect theantitumor response elicited by Salmonella-IL2.

In addition to NK, CD8+, and CD4+ lymphoid cells, we studied the role ofthe liver Kupffer cells on the antitumor response elicited bySalmonella-IL2. Salmonella species are facultative intracellularparasites that mainly localize in Kupffer cells and multiplyintracellularly. Murine Kupffer cells respond expansively to exogenouslyadministered IL-2 and participate in the induction of antigen-specificimmune responses. We did not find that the depletion of Kupffer cellsadversely affected the antitumor response elicited by Salmonella-IL2.

Attenuated Salmonella invades different tumor cell lines. The uniqueability of attenuated Salmonella to maintain immunogenicity after havinglost the ability to cause disease has led to more than a decade of studyof this organism's therapeutic potential in cancer patients. Salmonellacan grow under anaerobic and aerobic conditions, and can survive withinepithelial cells as well as macrophages. The precise mechanism ofinvasion and the antitumor effect seen with attenuated Salmonella incancer treatment is poorly understood. However, attenuated Salmonellaadministered intravenously seem to preferentially accumulate withinsubcutaneously placed tumors, as compared with its normal hostreservoir, the liver. Other researchers have replicated these findingsand have shown that attenuated Salmonella can halt the growth ofsubcutaneous tumors. However, how Salmonella accumulate within tumors isnot entirely clear. We investigated the ability of our attenuatedSalmonella-IL2 to invade at 5-, 10-, and 15-minute intervals, or tomultiply within different cancer cell lines: rat hepatocellularcarcinoma (Morris7777, hepatoma), mouse neuroblastoma (N2a,neuroblastoma), mouse methylcholanthrene-induced colon carcinoma(MCA-38, colon cancer), and mouse osteosarcoma (K7M2, osteosarcoma). Weused murine hepatocytes (liver) as a positive control and saline as anegative control (control).

We found that attenuated Salmonella-no-IL2 and Salmonella-IL2 displayedequal invasion efficiencies (percentage of intracellular Salmonellarecovered from inocula) into hepatocytes and all cancer cell lines (datanot shown). FIG. 23, Panel A shows that the ability of Salmonella-M2 toinvade cultured hepatocytes (liver) was much higher than that of anycancer cell line at all incubation times (p<0.05), displaying a stepwiselinear increase in bacterial invasion with increasing bacterial exposuretimes. Posthoc analysis of the Salmonella-IL2 invasion among cancer celllines revealed a divergence in invasion efficiency between neuroblastomaand hepatocellular carcinoma as compared with osteosarcoma or humancolon cancer cell lines. FIG. 23, Panel B is an expanded portion of FIG.23, Panel A excluding the data from the murine hepatocyte invasion.

Attenuated Salmonella replicates intracellularly in different tumor celllines. Once we observed that attenuated Salmonella differentiallyinvades tumor cells, we were curious to determine any differences inintracellular division by this organism within the different tumor celllines themselves. We defined the division efficiency as a measure ofintracellular proliferation, infected confluent suspensions of tumorcells with Salmonella-pIL2, and assessed intracellular growth of thebacteria after 24 hours. Again, we found no difference between thedivision efficiency of Salmonella-no-IL2 and Salmonella-IL2. FIG. 24shows that Salmonella-IL2 replicates with greater efficiency withinneuroblastoma and osteosarcoma cancer cells, as compared with liver,hepatoma, or colon cancer cells. Overnight incubation revealed greaterintracellular division of Salmonella-IL2 in neuroblastoma cells ascompared with hepatocytes (liver), hepatoma, or colon cancer cells. Theintracellular division of Salmonella-IL2 within osteosarcoma wassignificantly greater, as compared with hepatoma or colon cancer cells.Therefore, not only do attenuated Salmonella-no-IL2 and Salmonella-IL2display an enhanced invasion into neuroblastoma and osteosarcoma (ascompared with the other malignant cells) but also, the intracellularproliferation of the bacteria is augmented as well.

The invasion of wild-type S. typhimurium into enterocytes is awell-defined process. We previously demonstrated that attenuatedSalmonella-IL2 invasion into the enterocyte cell lines CaCo-2 and HT-29cells is significantly diminished as compared to its wild-typecounterpart. This finding partially accounts for its lower virulence andnear absence of Salmonella-associated gastroenteritis. Our attenuatedSalmonella-IL2 invasion into malignant cell subsets is not as effectiveas its invasion into hepatocytes, the normal colonization site for thisorganism. Furthermore, when we analyzed the invasiveness ofSalmonella-IL2, we found a difference between wild-type S. typhimuriumand attenuated Salmonella-IL2. Differences in the expression of cellsurface proteins may account for this observation. Wild-type S.typhimurium invasion into enterocytes depends on activation of plasmamembrane-associated GTP-binding proteins, such as CDC42 and/or Rac1. Thebinding of Salmonella to these proteins catalyzes a cascade ofintracellular signaling that results in membrane ruffling andmacropinocytosis of bacteria. Therefore, differences in expression ofRac1 and CDC42 could explain the variability of S. typhimurium invasioninto hepatocytes and malignant cell subsets.

Invasive Salmonella-IL2 invasion of neuroblastoma cells is visualized invivo. We and others have shown that Salmonella track to tumor tissue invitro, and we also devised a method to directly visualize Salmonella-IL2invasion of neuroblastoma cells in vivo. We modified our existingattenuated Salmonella strains, Salmonella-no-IL2 and Salmonella-IL2, bytransforming these bacteria with a commercially available plasmidcontaining the green fluorescent protein. Transformants were selected byusing the ampicillin resistance conferred by the GFP plasmid. TheGFP-transformed bacteria were used in our standard retroperitonealneuroblastoma model: 14 days after retroperitoneal injection of N2acells, we gavage-fed mice 10⁸ CFU of either Salmonella-no-IL2-GFP orSalmonella-IL2-GFP. Then, 1 week later, we sacrificed the mice,enumerated their tumors, prepared frozen tissue sections from thetumors, and examined the sections under the fluorescent microscope. OnlySalmonella-no-IL2-GFP or Salmonella-IL2-GFP constructs grew on agarplates containing ampicillin. We examined colonies on theampicillin-containing plates under the fluorescent microscope and foundthe expected green fluorescence at 488 nm. We found intracellularbacteria in the tissue sectioned from neuroblastoma extracted from micetreated with Salmonella-no-IL2-GFP or Salmonella-IL2-GFP and excited at488 nm. Intracellular Salmonella-IL2-GFP bacteria fluoresce morebrightly than the surrounding tissue. We also found small numbers offluorescent bacteria in the liver, spleen, and lungs. Tissue sectionsexamined from mice gavage-fed with non-GFP-transformed Salmonella-no-IL2and Salmonella-IL2 demonstrated no fluorescence when excited at 488 nm.

One oral dose of attenuated Salmonella nearly eliminates neuroblastoma.Given our finding of improved attenuated Salmonella invasion anddivision efficiency in neuroblastoma cells, we again used our standardvivo murine model of retroperitoneal neuroblastoma and investigated theantitumor effect of attenuated Salmonella. We found that treatment withSalmonella-no-IL2 and Salmonella-IL2 resulted in a significant reductionin both tumor volume (FIG. 25, Panel A) and tumor weight (FIG. 25, PanelB), as compared with saline controls. Tumor volume is calculatedassuming tumor shape as a sphere (4/3 πr³). When comparing reductionsbetween mice treated with Salmonella-no-IL2 and Salmonella-IL2, we foundstatistically significant decreases in tumor volume and in tumor weight.Cytokines proliferate in response to attenuated Salmonella. In an effortto look more closely at the mechanisms by which attenuated Salmonellaaffect neuroblastoma tumors, we evaluated, in our in vivoretroperitoneal neuroblastoma model, the systemic cytokines, IL-2, IL-6,IL-12, and interferon-gamma (IFN-γ) of cohorts of mice 14 days aftertreatment with saline (controls), with Salmonella-no-IL2, or withSalmonella-IL2. FIG. 26 shows a dramatic increase in the amount ofsystemic IL-6 in mice treated with Salmonella-IL2. IL-6 is a pleiotropiccytokine with a variety of immunomodulatory roles, including theactivation of cytotoxic T cells and NK cells. We previously showed IL-6to be important in reducing the tumor burden in our model of livermetastases of colon cancer. We found no upregulation of systemic IL-2,suggesting that the IL-2 produced by Salmonella-IL2 exerts its effectlocally.

Safety of Study Agent

Each of the family of attenuated strains, including our own χ4550 strainas described above, given orally to mice at doses up to 10⁹ organismsfailed to cause any mortality or morbidity. The genes for cya and crpare widely separated on the salmonella genome making reversion towild-type for both genes extremely unlikely. When parent strains weregrown to late log phase and plated on minimal agar medium with variouscarbohydrates that should not support growth, occasional mutants wereseen with the single deletion (cya−) strain χ4032, and very rare mutantswith the double deletion (cya−/crp−) strain χ4064. When these apparentmutants were re-administered to mice they remained avirulent. In humans,a cya−/crp− attenuated salmonella (derived from a different virulentstrain) using the asd− balanced lethal vector system (as in χ4550)showed little to no virulence in 22 human volunteers.²⁸ Over the courseof our experiments described above, the study agent has beenadministered to over 4000 mice without apparent adverse effect. As thestudy agent has never been administered to humans, this study willprovide for first data on human safety.

2.3 Study Disease: Carcinoma Metastatic to Liver

It is estimated that 130,000 new cases of colorectal carcinoma occur inNorth America per year. Of these patients, it is expected that 40 to 50percent will experience a recurrence within 5 years. Furthermore, it isknown that 75 to 80 percent of patients with a recurrence would have theliver as one of the involved sites for metastasis with 15 to 20 percenthaving the liver as the only site of failure.² Surgical excision of thehepatic metastases is the only potential for cure in these patients.Unfortunately, when a diagnosis of hepatic metastases is established,the majority of these patients have unresectable disease.^(1,2)

Unresectable metastatic carcinoma of the liver—regardless of the primarysite—continues to have a very poor prognosis despite recent advanceswith chemotherapeutic and radiotherapeutic strategies,chemoembolization, radiofrequency ablation, and cryotherapy.⁷ Thus, alarge body of research continues to be conducted, searching for aneffective means to combat unresectable metastatic carcinoma of theliver.

1. A method for treating primary and metastatic cancer, the methodcomprising administering to a patient a composition comprising aneffective amount of attenuated Salmonella typhimurium containing aplasmid carrying a coding sequence encoding a truncated humaninterleukin-2, wherein the coding sequence encoding the truncated humaninterleukin-2 comprises SEQ ID NO:
 1. 2. The method of claim 1 whereinthe attenuated Salmonella typhimurium containing the coding sequenceencoding truncated human interleukin-2 lacks the cyclic AMP and cAMPreceptor protein.
 3. The method of claim 1 wherein the attenuatedSalmonella typhimurium lacks the enzyme aspartate semialdehydedehydrogenase and the plasmid contains the enzyme aspartate semialdehydedehydrogenase, which renders the attenuated Salmonella typhimuriumharmless and simultaneously codes for truncated human IL-2.
 4. Themethod of claim 1 wherein the coding sequence encoding truncated humaninterleukin-2 has an eighty percent identity to SEQ ID NO:1.
 5. Themethod of claim 4 wherein the coding sequence encoding humaninterleukin-2 has an eighty five percent identity to SEQ ID NO:1.
 6. Themethod of claim 5 wherein the coding sequence encoding humaninterleukin-2 has a ninety percent identity to SEQ ID NO:1.
 7. Themethod of claim 6 wherein the coding sequence encoding humaninterleukin-2 has a ninety five percent identity to SEQ ID NO:1.
 8. Themethod of claim 1 wherein a dose containing approximately 10⁶ to 10⁸cells of the attenuated Salmonella typhimurium containing a plasmidcarrying the coding sequence encoding truncated human interleukin-2 isadministered once during treatment and a dose of approximately a halfteaspoon of an oil containing a high antioxidant concentration selectedfrom the group consisting of black raspberry oil, red raspberry oil,blackberry oil, marionberry oil, boysenberry oil, evergreen blackberryoil and black cumin oil is administered twice a day.
 9. A method fortreating primary and metastatic cancers, wherein the cancers treatedinclude hepatic metastases from adenocarcinoma, neuroblastoma, andpulmonary metastases from osteosarcoma, the method comprisingadministering to a patient a composition comprising an effective amountof attenuated Salmonella typhimurium containing a plasmid carrying acoding sequence encoding a truncated human interleukin-2, wherein thecoding sequence encoding the truncated human interleukin-2 comprises SEQID NO:
 1. 10. The method of claim 9 wherein the attenuated Salmonellatyphimurium containing the coding sequence encoding truncated humaninterleukin-2 lacks the cyclic AMP and cAMP receptor protein.
 11. Themethod of claim 9 wherein the attenuated Salmonella typhimurium lacksthe enzyme aspartate semialdehyde dehydrogenase and the plasmid containsthe enzyme aspartate semialdehyde dehydrogenase, which renders theattenuated Salmonella typhimurium harmless and simultaneously codes fortruncated human IL-2.
 12. The method of claim 9 wherein the codingsequence encoding truncated human interleukin-2 has an eighty percentidentity to SEQ ID NO:1.
 13. The method of claim 12 wherein the codingsequence encoding human interleukin-2 has an eighty five percentidentity to SEQ ID NO:1.
 14. The method of claim 13 wherein the codingsequence encoding human interleukin-2 has a ninety percent identity toSEQ ID NO:1.
 15. The method of claim 14 wherein the coding sequenceencoding human interleukin-2 has a ninety five percent identity to SEQID NO:1.
 16. The method of claim 9 wherein a dose containingapproximately 10⁶ to 10⁸ cells of the attenuated Salmonella typhimuriumcontaining a plasmid carrying the coding sequence encoding truncatedhuman interleukin-2 is administered once during treatment and a dose ofapproximately a half teaspoon of an oil containing a high antioxidantconcentration selected from the group consisting of black raspberry oil,red raspberry oil, blackberry oil, marionberry oil, boysenberry oil,evergreen blackberry oil and black cumin oil is administered twice aday.
 17. An anti-tumor agent comprising an effective amount ofattenuated Salmonella typhimurium containing a plasmid carrying a codingsequence encoding a truncated human interleukin-2, wherein the codingsequence encoding the truncated human interleukin-2 comprises SEQ IDNO:
 1. 18. An anti-tumor agent comprising an effective amount ofattenuated Salmonella typhimurium containing a plasmid carrying a codingsequence encoding a truncated human interleukin-2, wherein the codingsequence encoding the truncated human interleukin-2 comprises SEQ ID NO:1 and conservative modifications thereof.
 19. An anti-tumor agentcomprising an effective amount of attenuated Salmonella typhimuriumcontaining a plasmid carrying a coding sequence encoding a truncatedhuman interleukin-2, wherein the coding sequence encoding the truncatedhuman interleukin-2 comprises SEQ ID NO: 1 and conservativemodifications thereof, wherein SEQ ID NO:1 is derived from a synthetichuman interleukin-2 (SEQ ID NO: 5).
 20. A method treating cancer ofcomprising administering orally to a patient a composition comprising aninitial combined dose of an effective amount of attenuated Salmonellatyphimurium containing a plasmid carrying a coding sequence (SEQ IDNO: 1) encoding truncated human interleukin-2 and an oil containing ahigh antioxidant concentration selected from the group consisting ofblack raspberry oil, red raspberry oil, blackberry oil, marionberry oil,boysenberry oil, evergreen blackberry oil and black cumin oil, followedby daily administration of the oil containing a high antioxidantconcentration selected from the group consisting of black raspberry oil,red raspberry oil, blackberry oil, marionberry oil, boysenberry oil,evergreen blackberry oil and black cumin oil.
 21. The method of claim 19wherein the oil containing a high antioxidant concentration is extractedby using a high pressure press and maintaining the temperature of theoil below one hundred twenty degrees Fahrenheit.
 22. The method of claim19 wherein the daily dose of the oil having a high antioxidantconcentration is approximately one half teaspoon twice per day.
 23. Acomposition for treating cancer, comprising an orally administeredeffective amount of attenuated Salmonella typhimurium containing aplasmid carrying a coding sequence encoding truncated humaninterleukin-2 wherein the coding sequence encoding truncated humaninterleukin-2 comprises SEQ ID NO: 1, and an oil containing a highantioxidant concentration selected from the group consisting of blackraspberry oil, red raspberry oil, blackberry oil, marionberry oil,boysenberry oil, evergreen blackberry oil and black cumin oil